Persönlicher Status und Werkzeuge

Prof. Dr. Adnan Kastrati

Contact Details

Business card at TUMonline

Academic Career and Research Areas

The research interests of Prof. Kastrati (b. 1955) focus on optimizing treatment strategies in patients with acute coronary syndrome and in developing new drug-coated stents with an improved safety and efficacy profile. Another area is optimization of adjunctive peri-procedural antithrombotic therapy and evaluation of prognosis based on genetic and biochemical markers.  
Prof. Kastrati studied medicine in Tirana, Albania, where he graduated in 1979. He trained as a specialist and completed his postdoctoral studies in 1988. An Alexander von Humboldt research grant then took him to the 3rd medical clinic of Heidelberg University and the 1st medical clinic of TUM. Prior to his appointment to the Chair of Internal Medicine at TUM (2000), he worked as visiting researcher at the German Cardiac Center in Munich (DHM). Prof. Kastrati is currently chief physician and Deputy Director of the Cardiovascular Disease Clinic at DHM. He is Director of the Cardiac Catheter Laboratory and the ISARESEARCH Center.


    • Sven Effert Preis (2009)

    Key Publications

    Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, Khattab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schömig A: “Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.“ N Engl J Med. 2008; 359: 688-96.


    Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schömig A: “Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.” N Engl J Med. 2007; 356: 1030-9.


    Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A: “Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.” JAMA. 2006; 295: 1531-8.


    Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schömig A: “Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.” N Engl J Med. 2005; 353: 663-70.

    Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schühlen H, Schmitt C, Dirschinger J, Schömig A: „Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.” JAMA. 2005; 293: 165-71.